Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageAlnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Business segments
Q1 2026 · $1.12BThe company’s own SEC segment disclosure.
- Amvuttra$702.6M63%
- Rare$125.7M11%
- Collaborations$82.1M7%
- GIVLAARI$49.1M4%
- Royalty$49.0M4%
- Other License Programs$39.7M4%
- Other (5)$69.4M6%
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $2.46B in H1 2026 (quarter ended June 30, 2026), up 314% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $370M (15% of revenue). For the full year FY2025, revenue was $3.71B (+65% year on year) and net income $314M. Its largest product in 2026-Q1 was Amvuttra at $703M, 63% of the disclosed total, just ahead of Rare at 11%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
Ranks #57 of 145 by Smart Score